Foresee Pharmaceuticals Receives Fourth Positive Recommendation for CPP Drug Trial

Potential breakthrough in less frequent dosing for central precocious puberty treatment

Feb. 4, 2026 at 7:15am

Got story updates? Submit your updates here. ›

Foresee Pharmaceuticals has received a fourth positive recommendation from the independent Data and Safety Monitoring Board (DSMB) to continue the Casppian Phase 3 study of their leuprolide injectable emulsion (FP-001) for the treatment of central precocious puberty (CPP). This long-acting formulation aims to provide six months of puberty suppression with a single injection, reducing the burden of frequent monthly injections that are currently the standard of care.

Why it matters

CPP affects around 1 in 5,000 to 1 in 10,000 children, leading to shorter adult height, emotional challenges, and increased health risks if left untreated. Current GnRH agonist treatments require monthly or more frequent injections, which can be a significant source of stress for children and families. Foresee's FP-001 has the potential to be a 'game-changer' by dramatically reducing the dosing frequency.

The details

Foresee's FP-001 utilizes a sustained-release formulation to provide continuous suppression of gonadotropin secretion for six months with a single intramuscular injection. The positive results from the Casppian Phase 3 study, along with the DSMB's endorsement, suggest this goal is within reach. The study met its primary efficacy endpoint, demonstrating robust LH suppression, a key indicator of successful puberty control.

  • Foresee Pharmaceuticals received the fourth positive recommendation from the DSMB on February 4, 2026 to continue the Casppian Phase 3 study.

The players

Foresee Pharmaceuticals

A pharmaceutical company developing a long-acting injectable formulation (FP-001) for the treatment of central precocious puberty.

Dr. Sarah Klein

A pediatric endocrinologist at Boston Children's Hospital who specializes in central precocious puberty.

Got photos? Submit your photos here. ›

What they’re saying

“The frequent injections are a major pain point. While GnRH agonists are effective, the logistical and emotional toll of repeated injections can be substantial. A longer-acting formulation would be a game-changer.”

— Dr. Sarah Klein, Pediatric Endocrinologist, Boston Children's Hospital (newsy-today.com)

What’s next

Foresee Pharmaceuticals is preparing for the next regulatory steps with the Casppian Phase 3 study data. If approved, FP-001 could offer a significant improvement in the management of CPP by reducing the frequency of injections from monthly to twice a year.

The takeaway

This development from Foresee Pharmaceuticals represents a promising step forward in the treatment of central precocious puberty, potentially reducing the burden of frequent injections and improving quality of life for children and families affected by this condition.